歌禮制藥-B(01672.HK):甘萊FXR激動劑ASC42完成美國I期臨牀試驗首例受試者給藥
格隆匯 12 月 28日丨歌禮制藥-B(01672.HK)發佈公吿,公司全資附屬公司甘萊製藥有限公司(“甘萊”)的法尼醇X受體(FXR)激動劑、NASH候選藥物ASC42的美國I期臨牀試驗已完成首例受試者給藥。
該I期臨牀試驗是一項在美國開展的隨機、雙盲、安慰劑對照、單劑量與多劑量遞增研究,旨在評估ASC42在健康受試者中的安全性、耐受性、藥代動力學和藥效動力學特徵(生物標誌物-FGF19和C4)。該試驗還研究了食物對ASC42暴露量的影響。
ASC42是一種由甘萊完全自主研發的新型高效選擇性非甾類FXR激動劑。ASC42作為NASH候選藥物已於近日獲得美國食品藥品監督管理局(FDA)的快速通道資格認定。ASC42口服片劑由甘萊專有製劑技術開發,具有室温下穩定的特點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.